li001

Daraxonrasib (RMC-6236) delivered breakthrough results in the phase 3 RASolute 302 trial offering a major advance for patients with previously treated metastatic pancreatic ductal adenocarcinoma. The study enrolled 500 patients whose cancer had progressed after one prior chemotherapy regimen and compared oral daraxonrasib with standard chemotherapy options. Patients treated with daraxonrasib achieved a median overall […]

A phase 3 trial showed that the TMC-I regimen significantly improved survival in patients with platinum-sensitive, advanced head and neck squamous cell carcinoma receiving first-line palliative treatment. Conducted at the Tata Memorial Centre in India, the study compared TMC-I—an oral combination of methotrexate, erlotinib, and celecoxib plus ultra-low-dose nivolumab—with standard paclitaxel-carboplatin chemotherapy in 422 patients.

The phase 3 RAMPART trial found that adjuvant immunotherapy with durvalumab plus tremelimumab significantly reduced the risk of recurrence in patients with high-risk renal cell carcinoma following surgery. After a median follow-up of 3.5 years, the combination achieved a 3-year disease-free survival (DFS) rate of 80%, compared with 72% for active monitoring, translating to a

New subgroup data from the phase 3 ROSELLA trial show that adding relacorilant (Lifyorli) to nab-paclitaxel significantly improves survival for patients with platinum-resistant ovarian cancer, regardless of prior taxane treatment history. With a median follow-up of 24.8 months, patients receiving the combination therapy achieved a median overall survival of 16.0 months, compared with 11.9 months

Updated results from the RUBY phase 3 trial suggest that adding the immunotherapy drug dostarlimab to standard chemotherapy may offer the potential for long-term cure in patients with advanced or recurrent dMMR/MSI-H endometrial cancer. After a median follow-up of 55.6 months, patients receiving dostarlimab plus carboplatin and paclitaxel achieved a 4-year progression-free survival rate of